Definition
Abilify (Abilify) is an atypical antipsychotic medication indicated for acute and maintenance treatment of adult as well as adolescent (13–17 years of age) patients with Schizophrenia. The medication also is indicated for acute and maintenance treatment of manic and mixed episodes associated with Bipolar I Disorder with or without psychotic features in adult and pediatric (10–17 years of age) patients [1].
Description
Abilify was developed by Otsuka Pharmaceutical in Japan and jointly marketed in the United States with Bristol-Myers Squibb [1]. Clinical trials sponsored by the manufacturer have resulted in the Food and Drug Administration (FDA) approving the use of Abilify as an atypical antipsychotic [1–3]. The FDA first approved Abilify for the treatment of adult Schizophrenia in November, 2002. The medication received additional approval by the FDA for the acute and maintenance...
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bowles, T. M., & Levin, G. M. (2003). Aripiprazole: A new atypical antipsychotic drug. Annals of Pharmacotherapy, 37, 187–194.
Bristol-Meyers Squibb Company. (2008). Abilify prescribing information. Princeton, NJ: Bristol-Meyers Squibb Company.
DeLeon, A. (2004). Aripiprazole: A comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clinical Therapeutics, 26(5), 649–666.
Hammad, T. A., Laughren, T. P., & Racoosin, J. A. (2006). Suicidality in pediatric patients treated with antidepressant drugs. Archives of General Psychiatry, 63(3), 332–339.
Lawler, C. P., Prioleau, C., Lewis, M. M., Mak, C., Jiang, D., Schetz, J. A., et al. (1999). Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology, 20(6), 612–627.
Mottola, D. M., Kilts, J. D., Lewis, M. M., Connery, J. S., Walker, Q. D., & Jones, S. R. (2002). Functional selectivity of dopamine receptor agonists. I. selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase. The Journal of Pharmacology and Experimental Therapeutics, 301(3), 1166–1178.
Rugino, T. A., & Janvier, Y. M. (2005). Aripiprazole in children and adolescents: Clinical experience. Journal of Child Neurology, 20(7), 603–610.
Seifert, S. A., Schwartz, M. D., & Thomas, J. D. (2005). Aripiprazole (Abilify) overdose in a child. Clinical Toxicology, 43, 193–195.
Shapiro, D. A., Renock, S., Arrington, E., Louis, A. C., Li-Xin, L., Sibley, D. R., et al. (2003). Abilify, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology, 28, 1400–1411.
Stark, A. D., Jordan, S., Allers, K. A., Bertekap, R. L., Chen, R., & Kannan, T. M. (2007). Interaction of the novel antipsychotic Abilify with 5-HT1A and 5-HT2A receptors: Functional receptor-binding and in vivo electrophysiological studies. Psychopharmacology, 190, 373–382.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this entry
Cite this entry
Trotter, J.S., Davis, A.S. (2011). Abilify. In: Goldstein, S., Naglieri, J.A. (eds) Encyclopedia of Child Behavior and Development. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-79061-9_11
Download citation
DOI: https://doi.org/10.1007/978-0-387-79061-9_11
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-77579-1
Online ISBN: 978-0-387-79061-9
eBook Packages: Behavioral Science